Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Candel Therapeutics (Nasdaq: CADL) announced that on February 28, 2026 its Compensation Committee granted inducement stock options to one new employee to purchase 20,000 shares at an exercise price of $5.25 per share under the company's 2025 Inducement Plan.
Vesting: 25% after one year of service, then the remaining 75% vesting in 36 equal monthly installments, all subject to continued employment. The Plan was adopted on December 24, 2025 and the awards comply with Nasdaq Listing Rule 5635(c)(4).
Positive
- None.
Negative
- None.
News Market Reaction – CADL
In the Mar 3 session, CADL declined 3.91%, reflecting a moderate negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 24 | Conference presentation | Neutral | +2.4% | TD Cowen health care conference presentation and webcast availability details. |
| Feb 19 | Equity offering priced | Negative | -14.2% | Pricing of 18,348,624-share public offering at $5.45 expected to raise $100M. |
| Feb 19 | Equity offering proposed | Negative | -14.2% | Proposed $100M common stock offering under effective shelf registration. |
| Feb 19 | Royalty funding deal | Positive | -14.2% | $100M royalty funding agreement with RTW tied to CAN-2409 launch in prostate cancer. |
| Feb 11 | Conference participation | Neutral | -4.0% | Glioblastoma summit presentations on HSV platform and CAN-3110 program. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent financing and royalty news around CAN-2409 drew sharp negative reactions, while conference updates produced modest moves, showing sensitivity to capital-raising headlines.
Over the past weeks, CADL issued multiple financing and partnership updates tied to CAN-2409 and its pipeline. A proposed and then priced offering around $100 million coincided with -14.2% moves, while a $100 million royalty funding agreement with RTW shared that reaction despite being strategically supportive. In contrast, conference presentation announcements on Feb 11 and Feb 24 triggered relatively modest price changes, highlighting a pattern where capital structure news dominates trading behavior.
Key Terms
stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEEDHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today announced that on February 28, 2026, the Compensation Committee of Candel’s Board of Directors (the Board) granted to one new employee, stock options to purchase an aggregate of 20,000 shares of the Company’s common stock, with a per share exercise price of
The inducement stock options were made under the Company’s 2025 Inducement Plan (the Plan) and will vest with respect to
The above-described awards were each granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted pursuant to the terms of the Plan. The Plan was adopted by the Board on December 24, 2025.
About Candel Therapeutics
Candel is a clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Candel has established two clinical-stage multimodal biological immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) gene constructs, respectively. Aglatimagene besadenovec (CAN-2409 or aglatimagene) is the lead product candidate from the adenovirus platform. The Company recently completed successful phase 2a clinical trials of aglatimagene in non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC), and a pivotal, placebo-controlled, phase 3 clinical trial of aglatimagene in localized prostate cancer, conducted under a Special Protocol Assessment agreed with the U.S. Food and Drug Administration (FDA). The FDA also granted Fast Track Designation, Regenerative Medicine Advanced Therapy Designation to aglatimagene for the treatment of newly diagnosed localized prostate cancer in patients with intermediate-to-high-risk disease, Fast Track Designation in NSCLC, and both Fast Track Designation and Orphan Drug Designation to aglatimagene for the treatment of PDAC.
Linoserpaturev (CAN-3110) is the lead product candidate from the HSV platform and is currently in an ongoing phase 1b clinical trial in recurrent high-grade glioma, evaluating the effects of repeat linoserpaturev injections. Initial results were published in Nature and Science Translational Medicine and linoserpaturev received Fast Track Designation and Orphan Drug Designation from the FDA. Finally, Candel’s enLIGHTEN™ Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors.
For more information about Candel, visit: www.candeltx.com
Investor Contact
Theodore Jenkins
Vice President, Investor Relations and Business Development
Candel Therapeutics, Inc.
tjenkins@candeltx.com
Media Contact
Ben Shannon
ICR Healthcare
CandelPR@icrhealthcare.com
